What Is LL-37?
LL-37 is a naturally occurring peptide made up of 37 amino acids.
It belongs to a family of molecules known as antimicrobial peptides, or AMPs.
Humans produce LL-37 from a larger precursor protein called hCAP18, encoded by the CAMP gene.
When hCAP18 is processed, LL-37 is released as an active peptide.
It is produced by several types of cells, including neutrophils, macrophages, epithelial cells, and cells within the skin and respiratory and gastrointestinal tracts.
This places LL-37 directly at many of the body’s major barriers against the outside environment.
Why Are Researchers Interested in It?
LL-37 is interesting because it does much more than attack microorganisms.
Early research focused heavily on its antimicrobial properties.
Researchers later discovered that LL-37 also participates in:
immune signaling, inflammation, wound healing, cell migration, angiogenesis, tissue remodeling, and epithelial-barrier function.
That changed how scientists viewed the peptide.
Rather than simply behaving like a naturally occurring antibiotic, LL-37 appears to function as part of a broader communication system connecting microbial defense, inflammation, and tissue repair.
How Does LL-37 Work?
One of LL-37’s best-known properties comes from its positive electrical charge.
Many microbial membranes contain negatively charged components.
LL-37 can interact with these membranes, disrupt their structure, and interfere with microbial survival.
But direct antimicrobial activity is only part of the story.
LL-37 can also interact with mammalian receptors and signaling pathways.
Research has connected it with pathways involving:
FPR2, P2X7, EGFR signaling, Toll-like receptors, chemotaxis, cytokine signaling, and immune-cell recruitment.
The exact mechanism depends heavily on the cell type and biological environment.
That complexity is part of what makes LL-37 so interesting.
Antimicrobial Research
LL-37 has demonstrated antimicrobial activity against a wide range of microorganisms in laboratory research.
This includes various:
Gram-positive bacteria, Gram-negative bacteria, fungi, and some enveloped viruses.
Rather than targeting one specific bacterial enzyme like many conventional antibiotics, LL-37 can physically interact with microbial membranes.
That broad mechanism has made antimicrobial peptides an important area of research as scientists look for new strategies against difficult-to-treat infections.
However, antimicrobial activity observed in a laboratory does not automatically translate into an effective systemic antibiotic in humans.
Human tissues contain salts, proteins, enzymes, and other factors that can alter peptide activity.
LL-37 & the Innate Immune System
LL-37 is part of innate immunity.
Innate immunity is the body’s rapid first-line defense system.
Unlike antibodies, which recognize highly specific targets, innate immune mechanisms respond quickly to broad categories of biological threats.
LL-37 is released at barrier surfaces and during immune responses.
It can directly interact with microbes while simultaneously influencing immune cells.
That gives the peptide an unusual dual role:
it can participate in both microbial defense and immune communication.
Immune Modulation
LL-37 should not be thought of simply as an “immune booster.”
Its effects are much more nuanced.
Depending on the biological environment, LL-37 can increase some immune responses while reducing others.
For example, it can recruit immune cells toward sites of injury or infection while also interacting with inflammatory molecules such as bacterial lipopolysaccharide.
This ability to influence rather than simply amplify immunity is why researchers often describe LL-37 as immunomodulatory.
That distinction matters because successful healing requires an immune response that is strong enough to protect tissue but controlled enough to eventually resolve.
Inflammation Research
LL-37 has a complicated relationship with inflammation.
In some settings, it can help regulate inflammatory responses and neutralize microbial products.
In others, excessive or abnormal LL-37 activity has been associated with inflammatory disease.
This means LL-37 is not simply an anti-inflammatory peptide.
It is better understood as a regulator within inflammatory signaling.
Researchers are especially interested in understanding how concentration, tissue location, microbial exposure, and receptor activity determine whether LL-37 produces protective or inflammatory effects.
Wound-Healing Research
Wound healing is one of LL-37’s most compelling research areas.
The peptide is naturally expressed in wounded skin and participates in several processes required for repair.
These include:
keratinocyte migration, epithelial repair, angiogenesis, immune-cell recruitment, and communication between cells at the wound site.
Human wound research has also found altered LL-37 expression in chronic wounds compared with normally healing tissue.
This suggests LL-37 may be part of the body’s natural transition from injury toward tissue reconstruction.
Skin & Barrier Research
The skin is one of the body’s most important immune organs.
It must simultaneously maintain a physical barrier, tolerate beneficial microorganisms, defend against pathogens, and repair itself after injury.
LL-37 participates in all of these systems.
Skin cells can produce LL-37 in response to injury, infection, and inflammatory signals.
Researchers have therefore investigated it in areas involving:
wound healing, skin infection, barrier function, inflammation, acne, psoriasis, rosacea, and other dermatological conditions.
Interestingly, LL-37 levels can behave very differently between skin diseases.
That suggests the goal may not always be to increase LL-37.
In some conditions, excessive or dysregulated LL-37 signaling may itself contribute to inflammation.
Angiogenesis Research
New blood-vessel formation is essential during tissue repair.
Healing tissue requires oxygen and nutrients, and damaged vascular networks often need to be rebuilt.
LL-37 has demonstrated pro-angiogenic activity in experimental research.
It can stimulate endothelial-cell behavior involved in forming new blood vessels.
This gives LL-37 another potential role beyond antimicrobial defense.
It may help coordinate the transition from protecting damaged tissue to rebuilding it.
Cell Migration
Repairing tissue requires cells to move.
Keratinocytes must migrate across wounds.
Immune cells travel toward damaged or infected areas.
Endothelial cells move during new blood-vessel formation.
LL-37 has demonstrated effects on several of these cellular migration processes.
This is particularly interesting because it connects immune signaling directly with regenerative biology.
The same peptide helping alert the immune system may also participate in recruiting the cells needed to reconstruct damaged tissue.
Biofilm Research
Biofilms are organized microbial communities surrounded by a protective extracellular matrix.
They can be much more difficult to eliminate than free-floating microorganisms.
Biofilms are particularly important in chronic wounds and persistent infections.
Antimicrobial peptides, including LL-37, have therefore attracted interest in biofilm research.
Experimental studies suggest LL-37 can interfere with biofilm formation and influence microbial behavior at concentrations that may differ from those required to directly kill bacteria.
This has made LL-37 particularly interesting in research involving chronic wounds and antibiotic-resistant organisms.
Gut & Intestinal Research
LL-37 is also relevant to gastrointestinal biology.
The intestinal tract contains an enormous microbial population while maintaining a barrier between those organisms and internal tissues.
Antimicrobial peptides help maintain that balance.
LL-37-related signaling has been studied in intestinal epithelial defense, inflammation, microbial interactions, and mucosal immunity.
This creates overlap with other peptides in the library, particularly KPV and BPC-157, although their mechanisms are very different.
Respiratory Research
The respiratory tract is another major barrier exposed continuously to microorganisms and environmental particles.
Airway epithelial cells and immune cells can produce antimicrobial peptides as part of respiratory defense.
LL-37 has been studied in relation to bacterial and viral respiratory infections, airway inflammation, mucus environments, and pulmonary immune responses.
Researchers are especially interested in understanding when LL-37 contributes to protection and when excessive inflammatory signaling may become harmful.
Vitamin D & LL-37
One particularly interesting connection exists between vitamin D and LL-37.
The active vitamin D pathway can stimulate expression of the CAMP gene that produces the LL-37 precursor.
This discovery helped researchers understand one mechanism through which vitamin D participates in innate immune defense.
It also created an important bridge between nutrition, endocrine signaling, and antimicrobial immunity.
The relationship is considerably more complicated than saying vitamin D simply “boosts LL-37,” but the connection between vitamin D signaling and cathelicidin expression is well established.
LL-37 & Chronic Wounds
Chronic wounds often become trapped in prolonged inflammation and may contain persistent microbial communities and biofilms.
Because LL-37 participates in antimicrobial defense, immune signaling, angiogenesis, and epithelial migration, researchers have investigated whether manipulating this pathway could improve difficult wound environments.
This is one of the reasons LL-37 is particularly compelling scientifically.
Few peptides sit at the intersection of so many processes required for successful wound healing.
LL-37 & Autoimmune/Inflammatory Disease
LL-37 biology also demonstrates why more of a beneficial peptide is not always better.
In psoriasis, LL-37 can form complexes with self-DNA and stimulate immune pathways that contribute to inflammation.
Abnormal LL-37 signaling has also been investigated in rosacea and other inflammatory conditions.
This does not make LL-37 inherently harmful.
It shows that the peptide is an active immune regulator whose effects depend heavily on biological context.
That is an important consideration for any potential therapeutic application.
Cancer Research
LL-37 has also appeared in cancer biology research.
The findings are complex.
Depending on the tumor type and surrounding biological environment, LL-37-related signaling has been associated with both potentially protective and potentially tumor-supporting effects.
Researchers are studying how antimicrobial peptides influence tumor cells, immune responses, angiogenesis, and the tumor microenvironment.
Because the effects can differ dramatically between cancers, broad claims that LL-37 either “fights cancer” or “causes cancer” would both oversimplify the science.
Evidence Snapshot
Natural human biology: Strong. LL-37 is an established component of human innate immunity.
Antimicrobial evidence: Strong laboratory evidence across numerous microorganisms.
Immune-signaling evidence: Strong. LL-37 interacts with multiple immune and inflammatory pathways.
Wound-healing evidence: Promising, with substantial mechanistic and preclinical research and evidence connecting LL-37 with normal human wound biology.
Skin research: Extensive, particularly involving antimicrobial defense, wound healing, psoriasis, rosacea, and inflammatory signaling.
Angiogenesis and cellular migration: Strong mechanistic and experimental support.
Human therapeutic evidence: Developing. Experimental human work exists, but synthetic LL-37 has not become an established broadly approved antimicrobial or regenerative therapy.
What Do We Know?
LL-37 is a genuine human signaling molecule with several well-established biological functions.
It participates in innate immune defense.
It can interact directly with microorganisms.
It influences immune-cell signaling.
It participates in wound biology, cellular migration, and angiogenesis.
And its expression changes in response to injury, infection, and inflammatory signals.
That makes LL-37 considerably more biologically established than many peptides that exist primarily as experimental synthetic compounds.
What Are Researchers Still Trying to Determine?
The biggest challenge is learning how to harness LL-37’s useful properties without disrupting its carefully balanced immune functions.
Researchers continue to investigate:
optimal delivery methods, antimicrobial applications, chronic wounds, biofilms, inflammatory skin disease, gastrointestinal disease, respiratory infection, tissue regeneration, and modified LL-37-derived peptides.
Another major research goal is improving stability.
Like many peptides, LL-37 can be degraded by proteases.
Researchers are therefore developing modified antimicrobial peptides and delivery systems designed to preserve its useful properties while improving durability and tissue targeting.
Research & Regulatory Status
LL-37 is naturally produced by the human body, but that does not mean synthetic LL-37 products are automatically approved medications.
Synthetic LL-37 remains an investigational compound for most therapeutic applications.
Research has explored antimicrobial, wound-healing, immune, and regenerative uses, but there is currently no broadly FDA-approved synthetic LL-37 medication for infection, wound healing, immune enhancement, or anti-aging purposes.
This distinction is important:
the biology of LL-37 is well established, while therapeutic administration of synthetic LL-37 remains experimental.
Your Pep Resource Takeaway
LL-37 is one of the most fascinating peptides in the library because it sits directly between immunity and regeneration.
It isn’t simply an antimicrobial peptide.
It can interact with microbes, recruit immune cells, influence inflammatory signaling, promote cellular migration, participate in angiogenesis, and contribute to wound repair.
That gives researchers an unusually broad biological toolkit contained within a single 37-amino-acid peptide.
Its complexity is also the challenge.
LL-37 can be protective in one biological environment and contribute to inflammation in another.
That means future therapeutic development will likely depend on where, when, and how much LL-37 activity is produced rather than simply trying to increase it everywhere.
For researchers interested in innate immunity, antimicrobial peptides, chronic wounds, biofilms, skin biology, inflammation, barrier tissues, angiogenesis, and regenerative medicine, LL-37 is an exceptionally interesting peptide to watch.
Research Areas / Search Keywords
LL-37, LL37, LL 37 peptide, cathelicidin, cathelicidin antimicrobial peptide, CAMP gene, hCAP18, human cathelicidin, antimicrobial peptide, AMP peptide, innate immunity, innate immune peptide, natural antibiotic peptide, antimicrobial research, antibacterial peptide, antifungal peptide, antiviral peptide research, bacterial infection research, antibiotic resistance research, antimicrobial resistance, biofilm, biofilm peptide, chronic biofilm, wound biofilm, wound healing, wound repair, chronic wounds, skin healing, tissue repair, regenerative peptide, tissue regeneration, keratinocyte migration, cell migration, angiogenesis, blood vessel formation, endothelial cells, immune signaling, immune modulation, inflammatory signaling, inflammation research, cytokines, FPR2, P2X7, EGFR, Toll-like receptor, TLR signaling, lipopolysaccharide, LPS, skin barrier, skin immunity, psoriasis research, rosacea research, acne research, inflammatory skin research, gastrointestinal research, gut immunity, intestinal barrier, mucosal immunity, respiratory immunity, airway research, vitamin D LL-37, vitamin D cathelicidin, CAMP expression, immune defense, cancer peptide research, tumor microenvironment, experimental peptide, research peptide, peptide science.
Educational Disclaimer
This profile is provided for educational and research-information purposes only. Discussion of LL-37’s natural biological functions and laboratory, animal, antimicrobial, immune, wound-healing, or regenerative research does not establish that synthetic LL-37 is safe or effective for treating infections, wounds, inflammatory disorders, cancer, or another medical condition. Synthetic LL-37 is not an FDA-approved therapy for these uses.infection, autoimmune disease, wound healing, gastrointestinal disease, or other conditions.